{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:59:29Z","timestamp":1787961569527,"version":"build-2784847793"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T00:00:00Z","timestamp":1607040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T00:00:00Z","timestamp":1607040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinik M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Comprehensive genomic profiling identifying actionable molecular alterations aims to enable personalized treatment for cancer patients. The purpose of this analysis was to retrospectively assess the impact of personalized recommendations made by a multidisciplinary tumor board (MTB) on the outcome of patients with breast or gynecological cancers, who had progressed under standard treatment. Here, first experiences of our Comprehensive Cancer Center Molecular Tumor Board are reported.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>All patients were part of a prospective local registry. 95 patients diagnosed with metastatic breast cancer or gynecological malignancies underwent extended molecular profiling. From May 2017 through March 2019, the MTB reviewed all clinical cases considering tumor profile and evaluated molecular alterations regarding further diagnostic and therapeutic recommendations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>95 patients with metastatic breast or gynecological cancers were discussed in the MTB (68% breast cancer, 20% ovarian cancer, 5% cervical cancer, 3% endometrial cancer and 4% others). Genes with highest mutation rate were PIK3CA and ERBB2. Overall, 34 patients (36%) received a biomarker-based targeted therapy recommendation. Therapeutic recommendations were implemented in nine cases; four patients experienced clinical benefit with a partial response or disease stabilization lasting over 4\u00a0months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In the setting of a multidisciplinary molecular tumor board, a small but clinically meaningful group of breast and gynecological cancer patients benefits from comprehensive genomic profiling. Broad and successful implementation of precision medicine is complicated by patient referral at late stage disease and limited access to targeted agents and early clinical trials.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration number<\/jats:title>\n                <jats:p>284-10 (03.05.2018).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00404-020-05881-z","type":"journal-article","created":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T18:03:59Z","timestamp":1607105039000},"page":"1331-1345","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["NGS-guided precision oncology in metastatic breast and gynecological cancer: first experiences at the CCC Munich LMU"],"prefix":"10.1007","volume":"303","author":[{"given":"Elena","family":"Sultova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Benedikt","family":"Westphalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Kumbrink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kirchner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Mayr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Rudelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Ormanns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Heinemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus H.","family":"Metzeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp A.","family":"Greif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Burges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Trillsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Mahner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Harbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7268-0840","authenticated-orcid":false,"given":"Rachel","family":"Wuerstlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,4]]},"reference":[{"key":"5881_CR1","unstructured":"The Global Cancer Observatory, https:\/\/gco.iarc.fr Accessed 28 May 2020."},{"issue":"6","key":"5881_CR2","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1136\/archdischild-2013-304340","volume":"98","author":"S Behjati","year":"2013","unstructured":"Behjati S, Tarpey PS (2013) What is next generation sequencing? Arch Dis Child Educ Pract Ed 98(6):236\u2013238. https:\/\/doi.org\/10.1136\/archdischild-2013-304340","journal-title":"Arch Dis Child Educ Pract Ed"},{"issue":"17","key":"5881_CR3","doi-asserted-by":"publisher","first-page":"24860","DOI":"10.18632\/oncotarget.8391","volume":"7","author":"CG Kaderbhai","year":"2016","unstructured":"Kaderbhai CG, Bolidot R, Beltjens F et al (2016) Use of dedicated gene panel sequencing using next generation sequencing to improve the personalized care of lung cancer. Oncotarget 7(17):24860\u201324870. https:\/\/doi.org\/10.18632\/oncotarget.8391","journal-title":"Oncotarget"},{"issue":"33","key":"5881_CR4","doi-asserted-by":"publisher","first-page":"4877","DOI":"10.1200\/JCO.2009.26.5983","volume":"28","author":"DD Von Hoff","year":"2010","unstructured":"Von Hoff DD, Stephenson JJ Jr, Rosen P et al (2010) Pilot study using molecular profiling of patients\u2019 tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 28(33):4877\u20134883. https:\/\/doi.org\/10.1200\/JCO.2009.26.5983","journal-title":"J Clin Oncol"},{"issue":"32","key":"5881_CR5","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.1200\/JCO.2015.61.5997","volume":"33","author":"M Schwaederle","year":"2015","unstructured":"Schwaederle M, Zhao M, Lee JJ et al (2015) Impact of precision medicine in diverse cancers: a meta-analysis of phase II clinical trials. J Clin Oncol 33(32):3817\u20133825. https:\/\/doi.org\/10.1200\/JCO.2015.61.5997","journal-title":"J Clin Oncol"},{"key":"5881_CR6","doi-asserted-by":"publisher","first-page":"12316","DOI":"10.18632\/oncotarget.24384","volume":"9","author":"DS Haslem","year":"2018","unstructured":"Haslem DS, Chakravarty I, Fulde G et al (2018) Precision oncology in advanced cancer patients improves overall survival with lower weekly healthcare costs. Oncotarget. 9:12316\u201312322. https:\/\/doi.org\/10.18632\/oncotarget.24384","journal-title":"Oncotarget."},{"key":"5881_CR7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1756-8722-6-38","volume":"6","author":"JA Incorvati","year":"2013","unstructured":"Incorvati JA, Shah S, Mu Y et al (2013) Targeted therapy for HER2 positive breast cancer. J Hematol Oncol 6:38. https:\/\/doi.org\/10.1186\/1756-8722-6-38","journal-title":"J Hematol Oncol"},{"key":"5881_CR8","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s10147-007-0699-1","volume":"12","author":"T Maekawa","year":"2007","unstructured":"Maekawa T, Ashihara E, Kimura S et al (2007) The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias. Int J Clin Oncol 12:327\u2013340. https:\/\/doi.org\/10.1007\/s10147-007-0699-1","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"5881_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.hoc.2011.11.003","volume":"26","author":"LL Holman","year":"2012","unstructured":"Holman LL, Lu KH (2012) Genetic risk and gynecologic cancers. Hematol Oncol Clin North Am 26(1):13\u201329. https:\/\/doi.org\/10.1016\/j.hoc.2011.11.003","journal-title":"Hematol Oncol Clin North Am"},{"key":"5881_CR10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.semcdb.2016.08.025","volume":"64","author":"RE Ellsworth","year":"2017","unstructured":"Ellsworth RE, Blackburn HL, Shriver CD et al (2017) Molecular heterogeneity in breast cancer: state of the science and implications for patient care. Semin Cell Dev Biol 64:65\u201372. https:\/\/doi.org\/10.1016\/j.semcdb.2016.08.025","journal-title":"Semin Cell Dev Biol"},{"issue":"3","key":"5881_CR11","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00404-017-4292-1","volume":"295","author":"A Salomon-Perzy\u0144ski","year":"2017","unstructured":"Salomon-Perzy\u0144ski A, Salomon-Perzy\u0144ska M, Michalski B et al (2017) High-grade serous ovarian cancer: the clone wars. Arch Gynecol Obstet 295(3):569\u2013576. https:\/\/doi.org\/10.1007\/s00404-017-4292-1","journal-title":"Arch Gynecol Obstet"},{"key":"5881_CR12","unstructured":"The Asco Post Staff (2019) Alpelisib plus Fulvestrant approved for PIK3CA mutated breast cancer. https:\/\/www.ascopost.com\/issues\/june-10-2019\/alpelisib-plus-fulvestrant-approved-for-pik3ca-mutated-breast-cancer\/. Accessed 16 Sep 2019"},{"key":"5881_CR13","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andr\u00e9","year":"2019","unstructured":"Andr\u00e9 F, Ciruelos E, Rubovszky G et al (2019) Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med 380:1929\u20131940. https:\/\/doi.org\/10.1056\/NEJMoa1813904","journal-title":"N Engl J Med"},{"key":"5881_CR14","unstructured":"AGO. Alle aktuelle Empfehllungen. https:\/\/www.ago-online.de\/fileadmin\/ago-online\/downloads\/_leitlinien\/kommission_mamma\/2020\/Alle_aktuellen_Empfehlungen_2020.pdf. Accessed 24 April 2020."},{"key":"5881_CR15","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","volume":"366","author":"J Ledermann","year":"2012","unstructured":"Ledermann J, Harter P, Gourley C et al (2012) Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer. N Engl J Med 366:1382\u20131392. https:\/\/doi.org\/10.1056\/NEJMoa1105535","journal-title":"N Engl J Med"},{"key":"5881_CR16","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, Colombo N, Scambia G et al (2018) (2018) Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 379:2495\u20132505. https:\/\/doi.org\/10.1056\/NEJMoa1810858","journal-title":"N Engl J Med"},{"key":"5881_CR17","unstructured":"The Asco Post (2019). Olaparib improves outcomes in ovarian cancer. https:\/\/www.ascopost.com\/issues\/september-25-2019\/olaparib-improves-outcomes-in-ovarian-cancer\/. Accessed 29 Nov 2019"},{"issue":"2","key":"5881_CR18","doi-asserted-by":"publisher","first-page":"442","DOI":"10.3390\/cells9020442","volume":"9","author":"C D'Ambrosio","year":"2020","unstructured":"D\u2019Ambrosio C, Erriquez J, Arigoni M et al (2020) (2020) PIK3R1W624R Is an Actionable Mutation in High Grade Serous Ovarian Carcinoma. Cells 9(2):442. https:\/\/doi.org\/10.3390\/cells9020442","journal-title":"Cells"},{"issue":"45","key":"5881_CR19","doi-asserted-by":"publisher","first-page":"22730","DOI":"10.1073\/pnas.191138511","volume":"116","author":"L Zammataro","year":"2019","unstructured":"Zammataro L, Lopez S, Bellone S et al (2019) Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy. Proc Natl Acad Sci U S A 116(45):22730\u201322736. https:\/\/doi.org\/10.1073\/pnas.191138511","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"21","key":"5881_CR20","doi-asserted-by":"publisher","first-page":"7678","DOI":"10.1158\/0008-5472.CAN-04-2933","volume":"64","author":"IG Campbell","year":"2004","unstructured":"Campbell IG, Russell SE, Choong D et al (2004) Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64(21):7678\u20137681. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-2933","journal-title":"Cancer Res"},{"issue":"3","key":"5881_CR21","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S1470-2045(13)70611-9","volume":"15","author":"F Andr\u00e9","year":"2014","unstructured":"Andr\u00e9 F, Bachelot T, Commo F et al (2014) Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: A multicentre, prospective trial (SAFIR01\/UNICANCER). Lancet Oncol 15(3):267\u2013274. https:\/\/doi.org\/10.1016\/S1470-2045(13)70611-9","journal-title":"Lancet Oncol"},{"key":"5881_CR22","doi-asserted-by":"publisher","DOI":"10.1200\/jco2014.32.15_suppl.5591","author":"KE Oliver","year":"2014","unstructured":"Oliver KE, Xiao N, Spetzler D et al (2014) The impact of tumor molecular profile-directed treatment on survival in recurrent ovarian cancer. J Clin Oncol. https:\/\/doi.org\/10.1200\/jco2014.32.15_suppl.5591","journal-title":"J Clin Oncol"},{"issue":"16","key":"5881_CR23","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1093\/nar\/gkq603","volume":"38","author":"K Wang","year":"2010","unstructured":"Wang K, Li M, Hakonarson H (2010) ANNOVAR: Functional annotation of genetic variants from high throughput sequencing data. Nucleic Acids Res 38(16):e164. https:\/\/doi.org\/10.1093\/nar\/gkq603","journal-title":"Nucleic Acids Res"},{"key":"5881_CR24","unstructured":"https:\/\/www.ncbi.nlm.nih.gov\/clinvar\/ Accessed 20 March 2020"},{"key":"5881_CR25","doi-asserted-by":"publisher","DOI":"10.1200\/PO.16.00046","author":"WB Dalton","year":"2017","unstructured":"Dalton WB, Forde PM, Kang H et al (2017) Personalized medicine in the oncology clinic: implementation and outcomes of the Johns Hopkins Molecular Tumor Board. JCO Precis Oncol. https:\/\/doi.org\/10.1200\/PO.16.00046","journal-title":"JCO Precis Oncol"},{"issue":"3","key":"5881_CR26","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s10549-014-3117-1","volume":"147","author":"GS Jameson","year":"2014","unstructured":"Jameson GS, Petricoin EF, Sachdev J et al (2014) A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer. Breast Cancer Res Treat 147(3):579\u2013588. https:\/\/doi.org\/10.1007\/s10549-014-3117-1","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"5881_CR27","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1200\/JOP.2015.004127","volume":"11","author":"BA Parker","year":"2015","unstructured":"Parker BA, Schwaederl\u00e9 M, Scur MD et al (2015) Breast cancer experience of the molecular tumor board at the University of California, San Diego Moores Cancer Center. J Oncol Pract 11(6):442\u2013449. https:\/\/doi.org\/10.1200\/JOP.2015.004127","journal-title":"J Oncol Pract"},{"key":"5881_CR28","doi-asserted-by":"publisher","first-page":"3714","DOI":"10.1002\/cncr.32345","volume":"125","author":"D Dustin","year":"2019","unstructured":"Dustin D, Gu G, Fuqua SAW (2019) ESR1 mutations in breast cancer. Cancer 125:3714\u20133728. https:\/\/doi.org\/10.1002\/cncr.32345","journal-title":"Cancer"},{"issue":"13","key":"5881_CR29","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/S1470-2045(15)00188-6","volume":"16","author":"CL Tourneau","year":"2015","unstructured":"Tourneau CL, Delord JP, Gon\u00e7alves A et al (2015) Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol 16(13):1324\u20131334. https:\/\/doi.org\/10.1016\/S1470-2045(15)00188-6","journal-title":"Lancet Oncol"},{"issue":"6","key":"5881_CR30","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1158\/2159-8290.CD-16-1396","volume":"7","author":"C Massard","year":"2017","unstructured":"Massard C, Michiels S, Fert\u00e9 C et al (2017) High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 Trial. Cancer Discov 7(6):586\u2013595. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-1396","journal-title":"Cancer Discov"},{"key":"5881_CR31","unstructured":"The Asco Post (2017) ProfiLER trial: routine genomic testing feasible, but only a subset of patients may benefit. https:\/\/www.ascopost.com\/News\/55703. Accessed 27 July 2019"},{"issue":"3","key":"5881_CR32","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nrclinonc.2017.186","volume":"15","author":"JA Moscow","year":"2018","unstructured":"Moscow JA, Fojo T, Schilsky RL (2018) The evidence framework for precision cancer medicine. Nat Rev Clin Oncol 15(3):183\u2013192. https:\/\/doi.org\/10.1038\/nrclinonc.2017.186","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"5881_CR33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12916-019-1481-8","volume":"18","author":"SV Ramagopalan","year":"2020","unstructured":"Ramagopalan SV, Simpson A (2020) Sammon (2020) Can real-world data really replace randomised clinical trials? BMC Med. 18(1):13. https:\/\/doi.org\/10.1186\/s12916-019-1481-8","journal-title":"BMC Med."},{"key":"5881_CR34","unstructured":"Heinrich K, Miller-Phillips L, von Bergwelt-Baildon M et al (2020) The CCC LMU Molecular Tumorboard: clinical and molecular characteristics of the first 450 patients, DKK 2020. https:\/\/dkk.conference2web.com\/#!contentsessions\/45052. Accessed 15 May 2020"},{"issue":"13","key":"5881_CR35","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1200\/JCO.2013.52.4298","volume":"32","author":"SW Gray","year":"2014","unstructured":"Gray SW, Hicks-Courant K, Cronin A et al (2014) Physicians\u2019 attitudes about multiplex tumor genomic testing. J Clin Oncol 32(13):1317\u20131323. https:\/\/doi.org\/10.1200\/JCO.2013.52.4298","journal-title":"J Clin Oncol"},{"key":"5881_CR36","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/gim.2017.247","volume":"20","author":"K Schwarze","year":"2018","unstructured":"Schwarze K, Buchanan J, Taylor JC et al (2018) Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature. Genet Med 20:1122\u20131130. https:\/\/doi.org\/10.1038\/gim.2017.247","journal-title":"Genet Med"},{"issue":"2","key":"5881_CR37","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1159\/000489138","volume":"13","author":"A Rody","year":"2018","unstructured":"Rody A, Ettl J, Marm\u00e9 F, Prat A (2018) Molecular tumor boards. Breast Care (Basel) 13(2):141\u2013143. https:\/\/doi.org\/10.1159\/000489138","journal-title":"Breast Care (Basel)"},{"key":"5881_CR38","doi-asserted-by":"publisher","first-page":"10459","DOI":"10.1038\/s41598-020-67393-9","volume":"10","author":"D Hempel","year":"2020","unstructured":"Hempel D, Ebner F, Garg A et al (2020) Real world data analysis of next generation sequencing and protein expression in metastatic breast cancer patients. Sci Rep 10:10459. https:\/\/doi.org\/10.1038\/s41598-020-67393-9","journal-title":"Sci Rep"},{"issue":"7","key":"5881_CR39","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1007\/s10147-020-01661-6","volume":"25","author":"H Bourien","year":"2020","unstructured":"Bourien H, Lespagnol A, Campillo-Gimenez B et al (2020) Implementation of a molecular tumor board at a regional level to improve access to targeted therapy. Int J Clin Oncol 25(7):1234\u20131241. https:\/\/doi.org\/10.1007\/s10147-020-01661-6","journal-title":"Int J Clin Oncol"},{"key":"5881_CR40","unstructured":"Wuerstlein R, Harbeck N (2020) Pr\u00e4zisionsmedizin. Chancen f\u00fcr Forschung und Therapie. Individualisierte Diagnostik und Therapie des Mammakarzinoms: Hoffnung oder Realit\u00e4t? Frankfurter Forum f\u00fcr Gesellschafts- und Gesundheitspolitische Grundsatzfragen e.V. 40\u201349. http:\/\/frankfurterforum-diskurse.de\/wp-content\/uploads\/2020\/04\/Heft_21_Vortrag_5.pdf. Accessed 28 April 2020."},{"key":"5881_CR41","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12240","author":"J Seoane","year":"2014","unstructured":"Seoane J, De Mattos-Arruda L (2014) The challenge of intratumour heterogeneity in precision medicine. J Intern Med. https:\/\/doi.org\/10.1111\/joim.12240","journal-title":"J Intern Med"},{"key":"5881_CR42","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nature12625","volume":"501","author":"RA Burrell","year":"2013","unstructured":"Burrell RA, McGranahan N, Bartek J et al (2013) The causes and consequences of genetic heterogeneity in cancer evolu- tion. Nature 501:338\u2013345. https:\/\/doi.org\/10.1038\/nature12625","journal-title":"Nature"},{"key":"5881_CR43","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/nature12627","volume":"501","author":"PL Bedard","year":"2013","unstructured":"Bedard PL, Hansen AR, Ratain MJ et al (2013) Tumour heterogeneity in the clinic. Nature 501:355\u2013364. https:\/\/doi.org\/10.1038\/nature12627","journal-title":"Nature"},{"issue":"1","key":"5881_CR44","doi-asserted-by":"publisher","first-page":"CD006847","DOI":"10.1002\/14651858.CD006847.pub2","volume":"1","author":"EH Sim","year":"2018","unstructured":"Sim EH, Yang IA, Wood-Baker R et al (2018) (2018) Gefitinib for advanced non-small cell lung cancer. Cochrane Database Syst Rev. 1(1):CD006847. https:\/\/doi.org\/10.1002\/14651858.CD006847.pub2","journal-title":"Cochrane Database Syst Rev."},{"issue":"1","key":"5881_CR45","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13073-016-0364-2","volume":"8","author":"TL Stockley","year":"2016","unstructured":"Stockley TL, Oza AM, Berman HK et al (2016) Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT\/COMPACT trial. Genome Med 8(1):109. https:\/\/doi.org\/10.1186\/s13073-016-0364-2","journal-title":"Genome Med"},{"issue":"5","key":"5881_CR46","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/s41591-019-0424-4","volume":"25","author":"J Rodon","year":"2019","unstructured":"Rodon J, Soria JC, Berger R et al (2019) Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat Med 25(5):751\u2013758. https:\/\/doi.org\/10.1038\/s41591-019-0424-4","journal-title":"Nat Med"},{"key":"5881_CR47","doi-asserted-by":"publisher","DOI":"10.1200\/PO.18.00105","author":"R Hoefflin","year":"2018","unstructured":"Hoefflin R, Gei\u00dfler AL, Fritsch R et al (2018) personalized clinical decision making through implementation of a molecular tumor board: a german single-center experience. JCO Precis Oncol. https:\/\/doi.org\/10.1200\/PO.18.00105","journal-title":"JCO Precis Oncol"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-020-05881-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-020-05881-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-020-05881-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T14:06:51Z","timestamp":1618668411000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-020-05881-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,4]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["5881"],"URL":"https:\/\/doi.org\/10.1007\/s00404-020-05881-z","relation":{},"ISSN":["0932-0067","1432-0711"],"issn-type":[{"value":"0932-0067","type":"print"},{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,4]]},"assertion":[{"value":"14 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"CBW received personal and speakers\u2019 fees, reimbursement for travel and accommodation and honoraria for participance in advisory boards from Bayer, Celgene, Ipsen, Rafael Pharmaceuticals, RedHill, Roche, Servier, Shire\/Baxalta and Taiho and grant support by Roche. AJ received honoraria and reimbursement for travel and accommodation for participance in advisory boards and from speaker's bureau from Amgen, AstraZeneca, Biocartis, Bristo-Myers Squibb (BMS), Boehringer Ingelheim, Chinese Society for Pathology, German Society for Pathology, European Association for Cancer Research (EACR), International Association for Pathology (IAP), Merck-Serono, Merck-Sharp Dohme (MSD), Quality Initiative in Pathology (QuIP), Roche Pharma, Takeda; JK received honoraria and reimbursement for travel and accommodation for participance in advisory boards and from speaker's bureau from AstraZeneca, Novartis, Quality Initiative in Pathology (QuIP), Roche Pharma. TK received honoraria and reimbursement for travel and accommodation for participance in advisory boards from Amgen, AstraZeneca, Merck KGaA, MSD, Novartis, Pfizer, Roche; and from speaker's bureau from Merck and Astra Zeneca; from Merck and Roche research funding as well. KHM received honoraria from Celgene, Pfizer, Astellas, Daiichi Sankyo and Otsuka Pharma. AB received honoraria and reimbursement for travel and accommodation for participance in advisory boards from AstraZeneka, Roche and Tesaro. FT received research support, reimbursement for travel and accommodation for participance in advisory boards and from speaker's bureau from AstraZeneca, Clovis, Medac, PharmaMar, Roche, Tesaro\/GSK. SM received research support, advisory board, honoraria and travel expenses from AbbVie, AstraZeneca, Clovis, Eisai, GlaxoSmithKline, Medac, MSD, Novartis, Olympus, PharmaMar, Pfizer, Roche, Sensor Kinesis, Teva, Tesaro. NH received honoraria for lectures and\/or consulting from Agendia, Amgen, Astra Zeneca, BMS, Celgene, Daiichi-Sankyo, Genomic Health, Lilly, MSD, Novartis, Odonate, Pierre Fabre, Pfizer, Roche, Sandoz\/Hexal, Seattle Genetics. RW received honoraria for lectures and\/or consulting from Agendia, Amgen, Aristo, Astra Zeneca, Celgene, Clinsol, Daiichi-Sankyo, Eisai, Genomic Health, Glaxo Smith Kline, Hexal, Lilly, Medstrom Medical, MSD, Mundipharma, Nanostring, Novartis, Odonate, Paxman, Palleos, Pfizer, Pierre Fabre, PumaBiotechnolgogy, Riemser, Roche, Sandoz\/Hexal, Seattle Genetics, Tesaro Bio, Teva.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest statement"}},{"value":"The study received approval of the local ethics committee (study number: 284\u201310) and was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate and publication:"}}]}}